High-throughput in vitro drug assays have been impacted by recent advances in human induced 13 pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) technology and by contact-free all-14 optical systems simultaneously measuring action potential (AP) and Ca 2+ transient (CaTr). 15 Parallel computational advances have shown that in silico models can predict drug effects with 16 high accuracy. In this work, we combine these in vitro and in silico technologies and 17 demonstrate the utility of high-throughput experimental data to refine in silico hiPS-CM 18 populations, and to predict and explain drug action mechanisms. Optically-obtained hiPS-CM 19 AP and CaTr were used from spontaneous activity and under pacing in control and drug 20 conditions at multiple doses. 21 An updated version of the Paci2018 model was developed to refine the description of hiPS-22 CM spontaneous electrical activity; a population of in silico hiPS-CMs was constructed and 23 calibrated using the optically-recorded AP and CaTr. We tested five drugs (astemizole, 24 dofetilide, ibutilide, bepridil and diltiazem), and compared simulations against in vitro optical 25 recordings. 26 Our simulations showed that physiologically-accurate population of models can be obtained 27 by integrating AP and CaTr control records. Thus constructed population of models predicted 28 correctly the drug effects and occurrence of adverse episodes, even though the population was 29 optimized only based on control data and in vitro drug testing data were not deployed during 30 its calibration. Furthermore, the in silico investigation yielded mechanistic insights, e.g.
Introduction
• we optimized the model parameters to fit the same dataset of in vitro AP and CaTr 167 biomarkers used for (15), which have been recorded at 37°C;
168
• we validated the model against the same experimental protocols used for (15).
169
As a result, we obtained an improved version of our hiPS-CM model (Paci2019) blocking action on the other ion channels. This test was done on 4 models selected among the 217 ones that showed a pro-arrhythmic behaviour when administered astemizole.
218
Following drug application, we assessed the drug-induced changes on AP and CaTr rhythm was identified when the difference in cycle length between two consecutive AP greater 224 than 150%. 225 We looked also for two additional phenotypes, that we did not consider as abnormalities:
226 quiescence (40) and residual activity (42), mainly occurring during diltiazem administration 227 (see Results). If a model reacted to drug by producing AP whose peaks were greater than -228 40mV but smaller than 0mV, we labelled the model as residual activity. Conversely, we 229 considered the model quiescent, i.e. not producing anymore spontaneous AP, if during the last 230 15s the average membrane potential was smaller than -40mV or a potential residual activity 231 had all the peaks smaller than -40mV. The main difference between the two models is the shape of the INCX current. Before the repolarization (APD10, APD30, APD90); AP triangulation (AP Tri) computed as the ratio 271 between APD30-APD40 and APD70-APD80; CaTr DURATION; CaTr rise time from 10% to 272 50% (CaTr tRise10,50), 90% (CaTr tRise10,90), and to CaTr peak (CaTr tRise10,peak), decay time 273 from 90% to 10% (CaTr tDecay90,10), and CaTr rate (CaTr CL). in the in vitro experiments, was deployed to generate an initial population of 30,000 models.
286
As described in Methods, 3 different calibrations were performed (using AP only, CaTr only 287 or both AP and CaTr biomarkers), leading to 3 calibrated populations: AP_only, CaTr_only 288 and AP_CaTr, respectively.
289
A comparison of the AP and CaTr biomarkers for the 3 populations is shown in Figure 3 . (15), causes a reduction of Ca 2+ uptake, thus also contributing to a longer CaTr.
318
Overall, these results reveal important information contributed by the AP or CaTr biomarkers 319 in the calibration process to better capture the experimental recordings. For the rest of this 320 study, including the in silico drug trials, only the AP_CaTr population of 477 hiPS-CM 321 models was considered. The AP and CaTr traces for this population are shown in Figure 5 . Table 1 . 
352
Results for all biomarkers are shown in the Supporting Information, Figure S7-11 1 also with irregular rhythm).
379
In the simulations for 4 out of 5 tested compounds (astemizole, dofetilide, ibutilide and For diltiazem, we observed in silico only 1 EAD at D4 ( Figure S13 , Panels C), but no 421 tachyarrythmic rhythm, as in our in vitro experiments. In fact, most of our models (Table 3) 422 stopped their spontaneous AP, in agreement with what was observed in (40). However, 20 423 models at D4 showed a strong decrease in AP amplitude (in few cases peaks were recorded 424 below 0mV) and slight increase of frequency ( Figure S13, Panels A and B) . This low-amplitude were overall smaller in silico than in vitro. 548 We were able to obtain the same abnormality classes (Figure 7) observed in our in vitro data 549 and in (13), i.e. single and multiple EADs (panels A, B, C, D, E, F ) , with the addition of 550 repolarization failure (panels G and H), and irregular rhythms (panels I, J, K, L, M, N).
551
Conversely, the in silico models did not show tachyarrhythmias observed e.g. in (13) 
567
It is interesting to note that in our in vitro experiments, despite the reliable AP and CaTr 568 duration and triangulation increase, astemizole did not induce abnormalities, while they were such as APD prolongation and increased APD triangulation), may be due to a number of 575 reasons. One possibility is the lower temperature, though temperature-corrected in silico hiPS-
576
CMs revealed repolarization abnormalities. Another reason could be potentially higher IK1 (and 577 or IKs) in our high-density syncytial preparations compared to other studies.
578
Overall, hiPS-CMs proved to be an effective in vitro and in silico model to test drug-induced 579 adverse cardiac effects. Unexpected results in vitro and in silico for bepridil, considered a 580 highly cardiotoxic drug (3, 41), prompted further investigation. As reported in Table 3 , bepridil 581 triggered a very small amount of abnormalities in our in silico population. This is in agreement also blocks L-type calcium and peak and late sodium currents at higher concentrations. High 589 expression levels of calcium ion channels in hiPSC-CMs as compared to primary ventricular 590 tissue may have contributed to more attenuated cellular proarrhythmic effects of the drug as 591 compared to other drugs in the high TdP risk category.". We were able to test this idea in silico:
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